Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs

Veterinary Clinical Pathology

Volumn 34, Issue 3, 2005, Pages 237-242

  Diquelou A ^a,b   Barbaste, C ^b   Gabaig, A M ^c   Trumel, C ^b   Abella Bourges, N ^b   Guelfi, J F ^b   Bousquet Melou A ^a  

^a CNRS   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CHU PURPAN   (France)

Author keywords

Antifactor Xa activity; Coagulation test; Dog; Unfractionated heparin

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

EID: 26244449099     PISSN: 02756382     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-165X.2005.tb00047.x     Document Type: Article

References (26)

1. Boneu B. Les héparines [Heparin]. In: Sampol J, Arnoux D, Boutière B, eds. Manuel d'Hémostase. Paris, France: Elsevier; 1995:691-706.
2. Hirsh J. Relationship between dose, anticoagulant effect and the clinical efficacy of heparin. In: Lane DA, Björk I, Lindahl U, eds. Heparin and Related Polysaccharides. New York, NY: Plenum Press; 1992:283-295.
3. Couto CG. Disseminated intravascular coagulation in dogs and cats. Vet Med. 1999; June:547-554.
4. Moore DJ. Disseminated intravascular coagulation: a review of its pathogenesis, manifestations and treatment. J S Afr Vet Assoc. 1979;50:259-264.
5. Slappendel RJ. Disseminated intravascular coagulation. Vet Clin North Am. 1988;18:169-184.
6. De Laforcade AM, Freeman LM, Shaw SP, et al. Hemostatic changes in dogs with naturally occurring sepsis. J Vet Intern Med. 2003;17:674-679.
7. Maruyama H, Miura T, Sakai M, et al. The incidence of disseminated intravascular coagulation in dogs with malignant tumor. J Vet Med Sci. 2004;66:573-575.
8. Bakhshi S, Arya LS. Diagnosis and treatment of disseminated intravascular coagulation. Indian Pediatr. 2003;40:721-730.
9. Kellerman DL. Heparin therapy: what we do and don't know. In Proceedings of the 16th American College of Veterinary Internal Medicine Forum. San Diego, CA; May 22-25, 1998:438-139.
10. Byars TD, Wilson RC. Clinical pharmacology of heparin. J Am Vet Med Assoc. 1981;178:739-740.
11. Hellebrekers LJ, Slappendel RJ, Van den Brom WE. Effect of sodium heparin and antithrombin III concentration on activated plasma thromboplastin time in the dog. Am J Vet Res. 1985;46:1460-1462.
12. Mischke R, Jacobs C. The monitoring of heparin administration by screening tests in experimental dogs. Res Vet Sci. 2001;70:101-108.
13. Mischke R, Schuttert C, Grebe SI. Anticoagulation effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogs. Am J Vet Res. 2001;62:1887-1891.
14. Jacobs C, Grebe S, Kietzmann M, et al. Pharmakokinetik des unfraktionierten heparins Liquemin beim hund nach intravenöser und subkutaner injektion basierend auf der heparin aktivität [Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity]. Dtsch Tierarztl Wochenschr. 1999;106:478-481.
15. De Swart CAM, Nijmeyer B, Roelofs JMM, et al. Kinetics of intravenously administrated heparin in normal humans. Blood. 1982;60:1251-1258.
16. Van den Besselaar AMHP, Meeuwisse-Braun J, Jansen-Gruter R, et al. Monitoring heparin therapy: relationship between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost. 1990;63:16-23.
17. Briant L, Caranobe C, Saivin S, et al. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost. 1989;61:348-353.
18. Boneu B, Caranobe C, Cadroy Y, et al. Pharmacokinetic studies of standard unfractionated heparin and low molecular weight heparin in the rabbit. Semin Thromb Haemost. 1988;14:18-27.
19. 35S] heparin in the dog. Proc Soc Exp Biol Med. 1980;164:69-74.
20. Caranobe C, Petitou M, Dupouy D, et al. Heparin fractions with high and low affinity to antithrombin III are cleared at different rates. Thromb Res. 1986;43:635-641.
21. Boneu B, Caranobe C, Gabaig AM, et al. Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb Res. 1987;46:835-844.
22. Boneu B, Dol F, Caranobe C, et al. Pharmacokinetics of heparin and related polysaccharides. Ann N Y Acad Sci. 1989;74:1577-1582.
23. Caranobe C, Barret A, Gabaig AM, et al. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits. Thromb Res. 1985;40:129-133.
24. Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost. 1987;58:932-935.
25. Baker BA, Adelman MD, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med. 1997;157:2475-2479.
26. Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol. 1996;49:10-14.